Divestments
Arvelle Therapeutics
Dutch biotech company commercializing an epilepsy drug with unprecedented efficacy for refractory patients with partial onset seizures.
Key Facts
- Sector
Life Sciences
- Country
Netherlands
- Fund
LSP 6
- Entry
2019
- Exit
2021
Website
Do You Want to Know More?
We are eager to explore how we can achieve great things together.